Genevoyager
Wuhan, China genevoyager.ltd From their website, Nov 2026
- GLP
Work here? Claim this listing
About
Genevoyager provides AAV, vaccine, in vivo CAR-T, protein, pseudovirus, lentiviral, oncolytic virus, cell line, stem cell, and disease model services. It serves biopharma and research clients with CRO, CDMO, and technology-platform offerings in gene therapy and related biologics work.
Services
AAV CDMO
CDMO services for AAV development and manufacturing.
CDMO: development & manufacturing
Prophylatic/Therapeutic Vaccine Proprietary Technology
Proprietary technology for prophylactic and therapeutic vaccine work, including cell banking, virus banking, process development, analytical method development, and quality control.
CDMO: development & manufacturing
Lentiviral Vector-Mediated In Vivo CAR-T CRO/CDMO
CRO/CDMO services for lentiviral vector-mediated in vivo CAR-T with proprietary vector platform, molecular design, manufacturing, and analytics.
AAV Drug Screening
Screening service for AAV-related drug evaluation.
Kinase Drug Screening
Screening service for kinase-targeted drug evaluation.
Pharmacodynamic Evaluation
Pharmacodynamic evaluation services for drug candidates.
ADME, DMPK & toxicology
Pharmacokinetic Studies
Pharmacokinetic study services for drug candidates.
ADME, DMPK & toxicology
Non-GLP Nonclinical Safety Evaluation
Non-GLP nonclinical safety evaluation services.
ADME, DMPK & toxicology
21 more services
- AAV Neutralizing Antibody Assay
- Protein Expression
- Polypeptide Expression
- Virus-like Particles (VLPs)
- Lentiviral Packaging Service
- Oncolytic Viruses Service
- Cell Line Construction
- Gene-Modified Mesenchymal Stem Cell (MSC)
- In Vitro Diagnostic Raw Materials
- Neutralizing Antibody Assays
- One-Bac 4.0 System
- Molecular Cloning and Screening Platform
- Animal Disease Model Construction Platform
- Neutralizing Antibody Detection Platform
- Thyroperoxidase (TPO) — Diagnostic Raw Materials for GMP
- AAV Products
- Proprietary Technology for AAV / Vaccine / in vivo CAR-T CDMO
- Innovative Drug Non-clinical Evaluation CRO Service
- Directed Evolution of AAV CRO Service
- Protein and VLP Service
- Stem Cell Service
Capabilities
- Assays and studies
- AAV
- Lentivirus
- In vivo
- Antibodies
- Cell therapy
- Analytical development
11 more
- PK/PD
- Process development
- Peptides
- AAV neutralizing antibody assay
- Neutralizing antibody assays
- Neutralizing antibody detection
- AAV drug screening
- Kinase drug screening
- Pharmacodynamic evaluation
- Drug screening
- Pharmacokinetic studies
- Therapeutic areas
- Gene therapy
- Vaccines
- Alzheimer’s disease
- Atherosclerosis
- Autoimmune disease
- Infectious disease
Modalities and species
- Modalities
- Antibody
- Peptide
- Viral vector
- Cell therapy
- Vaccine
- Species and models
- Alzheimer’s Disease (AD) model
- AAV-PCSK9 atherosclerosis model
- AAV-1.3×HBV
- AAV-1.2×HDV
- Mesenchymal stem cell (MSC)
- One-Bac 4.0 System
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
GLPSelf-reported
ISO 9001Self-reported
Industries served
- Biotech
Details
- Type
- CRDMO
- Founded
- 2014
- Office
- 3675 Market Street, Suite 200, Philadelphia, PA 19104